AJJ Medtech Holdings Limited

As of June 30, 2026, AJJ Medtech Holdings Limited carries a market capitalization of 8.66M, placing it among publicly traded companies globally. Its enterprise value stands at 10.63M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, AJJ Medtech Holdings Limited has 1.73B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.06, and the price-to-book ratio stands at -2.11.

These figures are as of June 30, 2026. The EV/Sales ratio of 4.02 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 10.63M versus a market cap of 8.66M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, AJJ Medtech Holdings Limited maintains a current ratio of 0.28, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -48.42, indicating conservative leverage, while an interest coverage ratio of -31.45 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -99.87, reflecting losses generated across the asset base. Inventory turnover of 1.99 indicates how many times AJJ Medtech Holdings Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, AJJ Medtech Holdings Limited recorded 3,000.00 in income tax expense. The company reported a pretax loss of -3.36M and -3.37M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 15, 2026, AJJ Medtech Holdings Limited's stock has declined approximately 50.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

Over the twelve months ended June 30, 2026, AJJ Medtech Holdings Limited generated 2.64M in revenue and converted that into -3.37M in net income, yielding earnings per share of 0.00. EBITDA reached -2.80M, while operating income came in at -3.28M.

As of June 30, 2026, AJJ Medtech Holdings Limited holds 76,000.00 in cash and equivalents against 1.93M in total debt, resulting in a net debt position of 952,000.00. Total book value stands at -4.10M, with working capital of -4.25M providing operational flexibility.

AJJ Medtech Holdings Limited produced -1.37M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10,000.00 in capital expenditures, free cash flow totaled -1.38M - equivalent to 0.00 per share.

Over the twelve months ended June 30, 2026, AJJ Medtech Holdings Limited posted a gross margin of 32.77, reflecting its pricing power and cost economics. The operating margin of -123.95 and net profit margin of -127.43 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -17.00: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -16.22, meaning AJJ Medtech Holdings Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, AJJ Medtech Holdings Limited has an Altman Z-Score of -31.58, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.